Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Revenue of Ascendis Pharma A/S (ASND)
Revenue in 2023 (TTM): $266.72 M
According to Ascendis Pharma A/S's latest financial reports the company's current revenue (TTM) is $266.72 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ascendis Pharma A/S
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $266.72 M | $222.32 M | $-411,168,000 | $-474,144,000 | $-481,447,000 |
| 2022 | $51.17 M | $39.04 M | $-556,040,000 | $-577,817,000 | $-583,194,000 |
| 2021 | $7.78 M | $4.26 M | $-423,668,000 | $-383,944,000 | $-383,577,000 |
| 2020 | $6.95 M | $6.95 M | $-328,884,000 | $-419,174,000 | $-418,955,000 |
| 2019 | $13.38 M | $13.38 M | $-217,029,000 | $-218,250,000 | $-218,016,000 |
| 2018 | $10.58 M | $10.58 M | $-150,178,000 | $-130,491,000 | $-130,097,000 |
| 2017 | $1.53 M | $1.53 M | $-109,884,000 | $-124,374,000 | $-123,897,000 |
| 2016 | $4.61 M | $4.61 M | $-72,120,000 | $-68,732,000 | $-68,505,000 |
| 2015 | $8.12 M | $8.12 M | $-33,010,000 | $-33,574,000 | $-32,922,000 |
| 2014 | $13.98 M | $13.98 M | $-11,485,000 | $-10,340,000 | $-9,658,000 |
| 2013 | $20.41 M | $20.41 M | $5.68 M | $4.71 M | $4.08 M |
| 2012 | $15.58 M | $15.58 M | $1.73 M | $1.29 M | $1.25 M |